Bevurogant clinical trials
Also written BI 730357.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses bevurogant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 730357
- 10
Studies by the year they started
10 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Rosuvastatin (1) · Digoxin (1) · Metformin (1) · Furosemide (1)
Studies
Open first, then newest update. How each study uses bevurogant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357CompletedPhase 1Boehringer IngelheimNCT03279978Written as BI 730357
- A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT04590937Written as BI 730357
- To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT03004404Written as BI 730357
- A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the BloodCompletedPhase 1Boehringer IngelheimNCT04679948Written as BI 730357
- A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a TabletCompletedPhase 1Boehringer IngelheimNCT03804671Written as BI 730357
- Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent CiprofloxacinCompletedPhase 1Boehringer IngelheimNCT04147260Written as BI 730357
- This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are ToleratedCompletedPhase 1Boehringer IngelheimNCT03793621Written as BI 730357
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 730357 in the BloodCompletedPhase 1Boehringer IngelheimNCT03782987Written as BI 730357
- A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it isTerminatedPhase 2Boehringer IngelheimNCT03835481Written as BI 730357
- A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic ArthritisWithdrawnPhase 2Boehringer IngelheimNCT04680676Written as BI 730357
Codes
What other systems call bevurogant · ClinicalTrials.gg INT019033
- UNII (FDA) 1874HVK11IBEVUROGANTOne source FDA
- NCI Thesaurus C184901BevurogantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1874HVK11I | BEVUROGANT | One source FDA |
| NCI Thesaurus | C184901 | Bevurogant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.